NVasc
Atherton
About NVasc
NVasc is an early-stage ophthalmology company with a focus on treating blindness. It specializes in treating the leading causes of blindness through choroidal and retinal revascularization. The company has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels in the retina and choroid in mouse models of ischemic eye diseases. The company is planning to manufacture NVB001 which can be used in toxicokinetic studies and in early clinical trials in humans.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Last round: Series Unknown (Oct 2023)
Industries & Categories
Health Care, Medical Device, Therapeutics
Canonical: https://fsome.com/organization/nvasc-2727868 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.